Get the Stockscreener App
9.08
8.19%
-0.81
Pre-market:
9.26
0.18
+1.98%
Emergent Biosolutions Inc stock is traded at $9.08, with a volume of 1.15M.
It is down -8.19% in the last 24 hours and down -7.63% over the past month.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.
See More
Previous Close:
$9.89
Open:
$10
24h Volume:
1.15M
Relative Volume:
1.04
Market Cap:
$484.43M
Revenue:
$1.02B
Net Income/Loss:
$-757.20M
P/E Ratio:
-0.6152
EPS:
-14.76
Net Cash Flow:
$-257.90M
1W Performance:
-12.02%
1M Performance:
-7.63%
6M Performance:
+30.84%
1Y Performance:
+2.25%
1-Day Range:
$9.07
$10.21
1-Week Range:
$9.07
$10.39
52-Week Range:
$4.02
$13.41
Emergent Biosolutions Inc Stock (EBS) Company Profile
Name
Emergent Biosolutions Inc
Sector
Phone
240-631-3200
Address
300 PROFESSIONAL DR, GAITHERSBURG, MD
Compare EBS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EBS
Emergent Biosolutions Inc
|
9.08 | 519.42M | 1.02B | -757.20M | -257.90M | -14.76 |
|
ZTS
Zoetis Inc
|
115.89 | 51.60B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.06 | 44.51B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.60 | 42.35B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
24.28 | 28.04B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
474.72 | 20.52B | 3.08B | 1.24B | 1.07B | 25.61 |
Emergent Biosolutions Inc Stock (EBS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-30-24 | Initiated | H.C. Wainwright | Buy |
| Aug-22-24 | Initiated | Rodman & Renshaw | Buy |
| Mar-07-24 | Upgrade | The Benchmark Company | Hold → Buy |
| Nov-20-23 | Resumed | JP Morgan | Underweight |
| Aug-29-23 | Downgrade | The Benchmark Company | Buy → Hold |
| Apr-10-23 | Upgrade | The Benchmark Company | Hold → Buy |
| Mar-17-23 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-10-22 | Downgrade | The Benchmark Company | Buy → Hold |
| Apr-29-22 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jan-20-22 | Upgrade | The Benchmark Company | Hold → Buy |
| Nov-08-21 | Downgrade | The Benchmark Company | Buy → Hold |
| May-05-21 | Downgrade | Argus | Buy → Hold |
| Apr-07-21 | Initiated | The Benchmark Company | Buy |
| Feb-24-21 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Feb-19-21 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Jan-08-21 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-14-20 | Resumed | JP Morgan | Neutral |
| Jul-31-20 | Reiterated | Chardan Capital Markets | Buy |
| Sep-12-19 | Initiated | Guggenheim | Buy |
| Sep-04-19 | Upgrade | Wells Fargo | Market Perform → Outperform |
| Nov-02-18 | Upgrade | Goldman | Neutral → Buy |
| Aug-03-18 | Reiterated | Chardan Capital Markets | Buy |
| Jun-13-18 | Initiated | Argus | Buy |
| Apr-25-18 | Downgrade | Wells Fargo | Outperform → Market Perform |
| Jan-24-18 | Initiated | Goldman | Neutral |
| Jan-16-18 | Reiterated | Chardan Capital Markets | Buy |
| Jun-28-16 | Reiterated | Singular Research | Buy |
| Apr-15-16 | Initiated | Chardan Capital Markets | Buy |
| Mar-28-16 | Initiated | Singular Research | Buy |
| Feb-19-16 | Initiated | Wells Fargo | Outperform |
| May-15-14 | Initiated | Summer Street Research | Buy |
| May-31-11 | Reiterated | WBB Securities | Strong Buy |
| Jan-10-11 | Reiterated | Wedbush | Outperform |
| Nov-05-10 | Reiterated | Wedbush | Outperform |
| Aug-18-10 | Upgrade | WBB Securities | Buy → Strong Buy |
| Aug-06-10 | Reiterated | Caris & Company | Buy |
View All
Emergent Biosolutions Inc Stock (EBS) Latest News
Is Emergent BioSolutions Inc. stock undervalued at current price2025 Historical Comparison & AI Enhanced Trading Signals - newser.com
Why Emergent BioSolutions Inc. stock could outperform in 20252025 Trading Volume Trends & Precise Trade Entry Recommendations - newser.com
Is Emergent BioSolutions Inc. stock undervalued historicallyJuly 2025 News Drivers & Consistent Growth Stock Picks - newser.com
Why Emergent BioSolutions Inc. (ER4) stock is trending on social media2025 Institutional Moves & High Yield Stock Recommendations - newser.com
Will Emergent BioSolutions Inc. stock deliver consistent dividends2025 Earnings Surprises & Safe Swing Trade Setup Alerts - newser.com
Can Emergent BioSolutions Inc. stock deliver consistent EPS growth2025 Volume Leaders & Verified Entry Point Signals - newser.com
Will Emergent BioSolutions Inc. stock gain from green policiesJuly 2025 Opening Moves & Scalable Portfolio Growth Ideas - newser.com
How Emergent BioSolutions Inc. stock compares with tech leadersPortfolio Update Summary & Entry Point Strategy Guides - newser.com
How dovish Fed policy supports Emergent BioSolutions Inc. stockJuly 2025 Market Mood & High Accuracy Trade Signal Alerts - newser.com
Why millennials buy Emergent BioSolutions Inc. (ER4) stockPrice Action & AI Driven Stock Movement Reports - newser.com
Is Emergent BioSolutions Inc. stock resilient in recession scenariosPortfolio Gains Report & Daily Technical Forecast Reports - newser.com
Visual analytics tools that track Emergent BioSolutions Inc. performanceWeekly Investment Recap & Daily Stock Momentum Reports - newser.com
What makes Emergent BioSolutions Inc. stock appealing to growth investorsEarnings Overview Report & AI Powered Trade Plan Recommendations - newser.com
Understanding Emergent BioSolutions Inc.’s price movement2025 Major Catalysts & Weekly Sector Rotation Insights - newser.com
Published on: 2025-11-19 05:25:17 - newser.com
Published on: 2025-11-19 04:54:10 - newser.com
Chart based exit strategy for Emergent BioSolutions Inc.2025 Biggest Moves & Community Consensus Picks - newser.com
Reversal indicators forming on Emergent BioSolutions Inc. stockDay Trade & Daily Technical Stock Forecast Reports - newser.com
What technical patterns form on Emergent BioSolutions Inc. (ER4) stock charts - newser.com
Editor: 【Capital Growth】 - newser.com
Emergent’s NARCAN nasal spray marks 10 years since FDA approval By Investing.com - Investing.com Nigeria
Emergent’s NARCAN nasal spray marks 10 years since FDA approval - Investing.com India
Emergent BioSolutions marks 10-year anniversary of the U.S. FDA approval of Narcan nasal spray and reinforces its commitment to increasing naloxone access - MarketScreener
Emergent BioSolutions Marks 10-Year Anniversary of the U.S. FDA Approval of NARCAN® Nasal Spray and Reinforces its Commitment to Increasing Naloxone Access - The Manila Times
Emergent BioSolutions (NYSE: EBS) marks 10 years of NARCAN, 85M doses used - Stock Titan
Analyzing Emergent BioSolutions Inc. with multi timeframe chartsJuly 2025 Big Picture & Growth Focused Stock Reports - newser.com
Emergent Biosolutions Inc Stock (EBS) Financials Data
Revenue
Net Income
Cash Flow
EPS
6.17%
0.67%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):